This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Accelrys Challenges Industries To Speed Innovation By Transforming The Scientific Innovation Lifecycle

Stocks in this article: ACCL

SAN DIEGO, April 17, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today issued an industry-wide call to close the productivity gap from innovation through commercialization that is slowing product development and time-to-market and hampering competitiveness for science-driven organizations.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-challenges-industries-to-speed-innovation-by-transforming-the-scientific-innovation-lifecycle-147641195.html  

Currently, only 25 percent of projects in industries ranging from pharmaceuticals to aerospace result in the commercialization of new products, according to IDC Manufacturing Insights. Of the 25 percent of products that make it to market, 66 percent fail to meet original design or consumer expectations.

"There is growing consensus that new product development is increasingly ineffective – especially for science-driven innovation," said Joe Barkai, research vice president, product lifecycles strategies at IDC Manufacturing Insights. "Scientific-driven research and development organizations are at a critical juncture – their homegrown systems no longer meet the demands of today's fastest-to-market environment. They need to be managing the innovation cycle in a new way, and with the same rigor that they have managed their commercialization processes."

To accelerate innovation and profitability across industries, Accelrys is challenging science-driven organizations to focus on closing the productivity gap from innovation through commercialization. Accelrys also is introducing a scientifically aware enterprise platform as a component of a broader strategy to facilitate a new approach to effectively managing scientific innovation.

The Problem: The Productivity Gap

For science-driven organizations – particularly those developing products based on modeling at the atomic or molecular level – there is a productivity gap that spans the entire innovation-to-commercialization cycle. This productivity gap exists because traditional information technology solutions have proved incapable of adequately managing the complexity of scientific data and processes and the volumes of unstructured data characteristic of scientific R&D. Scientific processes, for example, are difficult to automate and track, and therefore information is hard to access and reuse during the scientific and product innovation and commercialization cycles. Critical scientific insights and context from the discovery and development stages are never transferred to the commercialization operations of a business because downstream enterprise software cannot handle the unstructured data generated in the R&D cycle. Key parts of the innovation process are consequently lost, along with actionable insights that could bring novel products to market more quickly and cost effectively.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs